Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] AML is in the business of manufacturing and marketing of male condoms and off late entered in female condoms. The company got converted in a public limited company in 2024, till then it was a proprietorship concern. The company posed growth in its top and bottom lines for the reported periods. The boosted bottom line from FY2024 raise eyebrows and in particular bumper profits reported for FY25 appears to be a window dressing for fetching fancy valuations. Based on its recent financial data, the issue appears greedily priced. Only well-informed/cash surplus investors may park moderate funds for medium term. Read detail review...
Anondita Medicare Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Anondita Medicare Limited | 9.60 | 9.60 | 21.32 | 38.10 | |||
| Cupid Ltd. | 1.52 | 1.52 | 12.75 | 110.38 | 11.96 | 13.92 |
Notes:
Anondita Medicare IPO Reviews, analysis and views by popular members. Read Anondita Medicare Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Post Recommendation Manage Recommendations
Note:
RHP